List of Excipients in Branded Drug WYNZORA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
MC2 Therapeutics Ltd	WYNZORA	calcipotriene and betamethasone dipropionate	73499-001	.ALPHA.-TOCOPHEROL, DL-
MC2 Therapeutics Ltd	WYNZORA	calcipotriene and betamethasone dipropionate	73499-001	BUTYLATED HYDROXYANISOLE
MC2 Therapeutics Ltd	WYNZORA	calcipotriene and betamethasone dipropionate	73499-001	CARBOMER INTERPOLYMER TYPE A

WYNZORA Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

WYNZORA is a prescription topical cream combining calcipotriene hydrate 0.005% and betamethasone dipropionate 0.064% for plaque psoriasis. Its commercial differentiation depends on the vehicle as much as the active ingredients. The formulation is designed to improve topical delivery, cosmetic acceptability, patient adherence, and use across multiple body sites compared with older ointment and foam products. The main commercial opportunity is to extend the vehicle platform into new strengths, indications, delivery formats, and licensed formulations while protecting the underlying formulation technology.

What is WYNZORA and how does its formulation differ?

WYNZORA Cream uses a proprietary PAD Technology vehicle. PAD refers to a formulation approach intended to support delivery of both active ingredients through a cream matrix while maintaining acceptable skin feel and stability.

The product contains:

Attribute	WYNZORA
Active ingredients	Calcipotriene hydrate and betamethasone dipropionate
Strength	Calcipotriene 0.005%; betamethasone dipropionate 0.064%
Dosage form	Topical cream
Indication	Plaque psoriasis in adults and pediatric patients aged 12 years and older
Application	Once daily for up to eight weeks
Commercial sponsor	MC2 Therapeutics
U.S. approval	FDA approval in 2020
Therapeutic class	Topical vitamin D analog plus corticosteroid
Key differentiation	Cream vehicle designed for delivery and cosmetic acceptability

The two active ingredients present a formulation challenge. Calcipotriene is a vitamin D analog with limited aqueous solubility, while betamethasone dipropionate is a highly potent corticosteroid with different solubility and partitioning behavior. A vehicle that improves delivery of one active can reduce stability, skin deposition, or uniformity of the other.

WYNZORA’s excipient strategy therefore has four technical objectives:

1. Maintain both active ingredients in a stable and uniform formulation.
2. Promote deposition in the epidermis and dermis without excessive systemic exposure.
3. Provide a cream texture that patients will use consistently.
4. Support manufacturing, packaging, and shelf-life requirements.

What excipients are used in WYNZORA?

The FDA labeling identifies mineral oil, isopropyl myristate, liquid paraffin, polyoxyl 20 cetostearyl ether, cetostearyl alcohol, white petrolatum, and purified water as inactive ingredients.[1]

Excipient	Likely formulation role
Mineral oil	Emollient, oil-phase vehicle, occlusive effect
Liquid paraffin	Emollient, viscosity and oil-phase control
White petrolatum	Occlusive emollient and skin-protection component
Isopropyl myristate	Emollient and penetration-enhancing component
Cetostearyl alcohol	Structuring agent, viscosity modifier, emulsion stabilizer
Polyoxyl 20 cetostearyl ether	Nonionic emulsifier and interfacial stabilizer
Purified water	Aqueous phase and processing medium

The inactive ingredients are conventional pharmaceutical excipients, but their ratios, processing conditions, particle-size distribution, phase structure, and interaction with the active ingredients may provide meaningful formulation differentiation. In topical products, the commercial value often rests in the composition and manufacturing process rather than in the individual excipients.

How does the WYNZORA vehicle support product differentiation?

WYNZORA competes against products that use different delivery systems, including ointments, creams, foams, and separate vitamin D analog and corticosteroid products.

Compared with ointments

Ointments can provide strong occlusion and effective delivery but may be greasy, difficult to spread, and poorly accepted on visible or hairy areas. WYNZORA’s cream format is positioned to improve cosmetic acceptability and reduce the adherence burden associated with greasy formulations.

Compared with foams

Foams can spread rapidly and may be useful on the scalp and large body areas. They can require specialized packaging, propellants, and manufacturing systems. WYNZORA avoids the need for a pressurized foam container while preserving a differentiated delivery claim through its cream vehicle.

Compared with conventional creams

A conventional generic cream containing the same active ingredients could match the labeled strengths but may not reproduce WYNZORA’s microstructure, release profile, skin deposition, or sensory attributes. Those characteristics can support formulation patents, regulatory differentiation, and brand loyalty.

The commercial challenge is that topical products are often substituted based on price and payer formulary position. Vehicle differentiation must be clinically visible to prescribers and patients to withstand generic or lower-cost competition.

What formulations are protected by WYNZORA’s technology?

The core protection strategy is likely to center on formulation composition, the physical organization of the vehicle, manufacturing parameters, and therapeutic use. The commercial value of these claims depends on whether they cover:

• Specific ratios of oil-phase and water-phase components.
• Use of mineral oil, paraffin, petrolatum, isopropyl myristate, fatty alcohol, and nonionic surfactant systems.
• Physical properties such as viscosity, droplet size, phase behavior, or rheology.
• Enhanced delivery or deposition of calcipotriene and betamethasone dipropionate.
• Once-daily treatment regimens.
• Use on specific body sites or in specific patient groups.
• Combination therapy with other psoriasis treatments.
• Packaging systems that preserve dose uniformity and stability.

A competitor could seek approval through an abbreviated new drug application for an equivalent topical product or develop a non-infringing formulation with different excipients and microstructure. The strength of WYNZORA’s formulation estate depends on claim breadth and whether the claims require a particular excipient combination or a measurable performance profile.

The FDA Orange Book status and current patent listing should be evaluated against the latest FDA publication before making a launch or litigation decision. The label and FDA approval record establish the approved product and formulation but do not, by themselves, establish the complete scope or remaining life of the patent estate.[1,2]

When does WYNZORA lose exclusivity?

WYNZORA received FDA approval in 2020. FDA approval does not provide a single expiration date for all commercial exclusivity. Market protection may reflect several separate rights:

Protection category	Relevance to WYNZORA
New drug exclusivity	Depends on the specific FDA designation and approval record
Formulation patents	May cover the cream vehicle, composition, or manufacturing process
Method-of-use patents	May cover treatment regimens, patient populations, or body sites
Pediatric exclusivity	Could extend qualifying patent or exclusivity periods if granted
Trademark protection	Protects the WYNZORA brand but does not block generic entry
Trade secrets	May protect manufacturing know-how and process controls

For a topical product, patent expiry analysis must distinguish between the earliest generic pathway and the last commercially meaningful patent. A generic applicant may challenge selected patents through Paragraph IV certification, design around formulation claims, or wait for patent expiry while relying on a different vehicle.

What Paragraph IV challenges and litigation risks affect WYNZORA?

A Paragraph IV challenge would assert that a listed patent is invalid, unenforceable, or not infringed. The brand company could respond with patent litigation, potentially triggering a 30-month stay of FDA approval for the challenged abbreviated new drug application, subject to the statutory framework and litigation events.[3]

The primary litigation risks are likely to involve:

• Whether the generic product uses the claimed excipient combination.
• Whether the generic reproduces a claimed physical property of the cream.
• Whether formulation claims are enabled across their full scope.
• Whether method-of-use claims are infringed by the generic label.
• Whether manufacturing-process claims can be detected from the finished product.
• Whether the formulation patent estate survives obviousness challenges based on earlier calcipotriene and corticosteroid products.

The most defensible claims are usually those tied to measurable product attributes or specific composition ranges. Broad claims covering familiar excipients can face greater obviousness exposure unless the formulation demonstrates an unexpected delivery, stability, or tolerability result.

How strong is the WYNZORA patent estate?

WYNZORA’s patent strength depends on the degree to which its patents protect the integrated vehicle rather than a list of conventional ingredients.

Stronger protection characteristics

• Narrow but technically specific composition ranges.
• Demonstrated improvement in active-ingredient stability.
• Distinctive release or skin-deposition data.
• Claims covering a reproducible cream microstructure.
• Manufacturing steps that are difficult to replicate without using the claimed process.
• Clinical or pharmacokinetic evidence linking the vehicle to improved performance.

Weaker protection characteristics

• Claims that recite only well-known topical excipients.
• Broad claims without comparative performance data.
• Formulation claims that can be avoided by changing one inactive ingredient.
• Method-of-use claims that overlap with the approved label of older combination products.
• Patents with limited remaining term relative to development and litigation timelines.

The vehicle can still create commercial barriers even where patent protection is limited. Manufacturing scale-up, analytical method transfer, comparative clinical requirements, device compatibility, and payer contracting can delay effective competition.

What commercial opportunities exist for WYNZORA excipient technology?

New dosage forms

The PAD platform could support development of:

• A scalp-compatible cream or lotion.
• A sprayable formulation for large body areas.
• A lower-residue cream for intertriginous areas.
• A gel-cream for humid climates.
• A foam or mousse using the same active combination.
• A pump or metered-dose package that improves dose control.

Each format would require separate stability, delivery, preservative, packaging, and regulatory assessments. A new dosage form could support a supplemental application or a new product strategy, depending on the extent of formulation and clinical changes.

New strengths and treatment regimens

Potential lifecycle products include lower-potency corticosteroid combinations, reduced-frequency maintenance therapy, and formulations tailored for sensitive sites. These programs would require evidence that the revised strength or regimen preserves efficacy while reducing steroid exposure and adverse-event risk.

Pediatric and geriatric applications

The product is already labeled for patients aged 12 years and older.[1] A pediatric lifecycle strategy could target younger patients, but it would require age-appropriate safety evidence, dosing instructions, and potentially different packaging or applicator design.

Combination therapy

WYNZORA could be positioned with biologics, phototherapy, moisturizers, or nonsteroidal topical agents. The commercial opportunity is greatest where the vehicle improves patient persistence during induction or supports transition to maintenance therapy.

Licensing and platform partnerships

The excipient and vehicle technology could be licensed to companies with:

• Dermatology sales forces.
• Existing generic topical portfolios.
• Consumer-health infrastructure.
• Regional manufacturing capacity.
• Specialty-pharmacy distribution.
• Complementary products for eczema, seborrheic dermatitis, or other inflammatory dermatoses.

A platform license would have greater value if it includes formulation know-how, analytical methods, scale-up protocols, and rights to use the technology with multiple active ingredients. A single-product license is easier to execute but offers less long-term platform value.

What manufacturing and IP barriers affect commercial expansion?

The formulation uses a multiphase cream system. Scale-up risks include emulsion uniformity, heat history, mixing shear, active dispersion, phase separation, viscosity drift, and fill-weight variability. These parameters can affect dose delivery and product performance even when the nominal ingredient list is unchanged.

Packaging is also commercially relevant. The container must protect the formulation from contamination, preserve active stability, support consistent dispensing, and limit residual product loss. A pump or tube can provide a secondary barrier if it improves dosing accuracy or reduces microbial exposure.

Manufacturing know-how may therefore create a practical barrier independent of patent scope. A generic competitor may reproduce the listed ingredients but fail to match the product’s physical attributes or demonstrate pharmaceutical equivalence without extensive development work.

How does WYNZORA compare with competing topical psoriasis products?

Product type	Main advantage	Main limitation	WYNZORA opportunity
Calcipotriene/betamethasone ointment	Established efficacy and occlusion	Greasy texture and lower convenience	Position cream as more acceptable for daily use
Calcipotriene/betamethasone foam	Fast spreading and strong patient usability	Higher packaging and delivery-system complexity	Offer a non-pressurized cream alternative
Separate calcipotriene and steroid products	Flexible prescribing	More applications and lower convenience	Emphasize fixed-combination simplicity
Generic combination products	Lower price	Vehicle may differ from the reference product	Defend through formulation performance and brand adherence
Nonsteroidal topical agents	No corticosteroid exposure	Different efficacy and cost profile	Use as an induction or combination option

What is the FDA regulatory and commercial status of WYNZORA?

WYNZORA is an FDA-approved prescription drug for plaque psoriasis. Its regulatory value comes from the approved fixed combination, once-daily dosing, cream dosage form, and defined patient population.[1,2]

The commercial model depends on specialty dermatology prescribing, payer coverage, patient access programs, and the ability to demonstrate that the vehicle improves actual use. Claims based solely on cosmetic elegance are less durable than claims supported by adherence, treatment-area coverage, tolerability, or patient-reported outcomes.

Revenue exposure is concentrated in the U.S. psoriasis market and depends on net price, formulary placement, prescription volume, and the timing of generic entry. Without verified current sales data, a reliable revenue forecast cannot be assigned.

Key Takeaways

• WYNZORA’s main differentiation is its proprietary cream vehicle, not the novelty of calcipotriene or betamethasone dipropionate individually.
• The excipient system combines emollients, occlusives, a fatty alcohol structurant, a nonionic emulsifier, and water.
• Commercial value depends on reproducible formulation performance, patient acceptability, and manufacturing know-how.
• The strongest IP position would protect composition ranges, cream microstructure, measurable delivery attributes, and manufacturing controls.
• Lifecycle opportunities include scalp products, lower-residue formulations, new strengths, maintenance regimens, pediatric extensions, and regional licensing.
• Generic risk depends on the current Orange Book listings, remaining patent term, Paragraph IV activity, and the ease of designing around the vehicle.
• A competitor that copies the active ingredients but changes the excipient system may avoid some formulation claims while facing separate equivalence and performance-development challenges.

FAQs

Can WYNZORA’s excipients be substituted in a generic product?

Yes. A generic applicant may use different inactive ingredients if the product meets applicable FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling. Substitution can also be used as a design-around strategy against formulation claims.

Does isopropyl myristate make WYNZORA a penetration-enhanced product?

Isopropyl myristate is commonly used as an emollient and penetration-enhancing excipient. Its legal and regulatory significance depends on the claimed formulation, concentration, product performance, and evidence linking it to active delivery.

Is WYNZORA suitable for large-area psoriasis treatment?

The approved labeling establishes dosing limits and treatment duration. Use across large areas must follow the FDA label because corticosteroid exposure and calcipotriene-related safety considerations depend on total treated surface area and cumulative dose.[1]

Could WYNZORA technology be used with nonsteroidal psoriasis drugs?

Potentially. The vehicle could be adapted for other poorly soluble or lipophilic dermatology compounds, but each active ingredient would require independent compatibility, stability, delivery, safety, and regulatory development.

What is the most valuable commercial asset in the WYNZORA platform?

The highest-value asset is the integrated formulation and manufacturing package: excipient ratios, process controls, physical-performance specifications, analytical methods, and clinical evidence connecting the vehicle to patient usability and topical delivery.

References

1. U.S. Food and Drug Administration. (2020). WYNZORA Cream prescribing information. FDA.
2. U.S. Food and Drug Administration. (2020). Drugs@FDA: WYNZORA. FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.